Our work revealed that miR-9-5p can modulate the NF-κB–Nrf2 axis in CD4+ T cells, improve the differentiation of CD4+IL-10+ T cells, and ameliorate AAA-related immunological dysfunction. The gene discussed is NFKB1; the disease is triple-A syndrome.